Apr 18, 2019
Amgen reveals the price of EVENITY Amgen has set the price of its newly launched Osteoporosis drug Romosozumab (Evenity). Worth USD 21,900 per annum or USD 1,825 a month, the bone-building drug was approved by the FDA recently for the treatment of Osteoporosis in postmenopausal women and now will be available i...
Read More...
Oct 11, 2018
Cytosen Therapeutics and KBI Biopharma pair up to manufacture NK cells and Nanoparticles CytoSen Therapeutics and KBI Biopharma paired up to manufacture therapeutic Natural Killer Cell by using a closed system manufacturing process. According to the initial collaboration, KBI will be subjected to manufactur...
Read More...
A New Era for Multiple Myeloma Treatment: Bispecific Antibodies Enter the Fray
Jun 10, 2025
LEQEMBI: A New Hope for Alzheimer’s Disease Patients
Feb 12, 2025
Newsletter/Whitepaper